Please login to the form below

Not currently logged in
Email:
Password:

RMS

This page shows the latest RMS news and features for those working in and with pharma, biotech and healthcare.

Merck takes evobrutinib for MS into phase 3, on mixed data

Merck takes evobrutinib for MS into phase 3, on mixed data

The principal investigator in the EVOLUTION RMS 2 trial – Xavier Montalban of the University of Toronto and St. ... Even with the most effective therapies for RMS, more than 50% of patients experience clinical or subclinical disease activity,” he said

Latest news

  • Novartis scores promising phase 3 MS study Novartis scores promising phase 3 MS study

    Ofatumumab, if approved, could be a highly attractive treatment option for a broad RMS patient population, including early MS,” said John Tsai, head global drug development and chief medical officer, Novartis.

  • Roche's MS drug Ocrevus awarded priority review by FDA Roche's MS drug Ocrevus awarded priority review by FDA

    Roche is seeking a licence for the drug to treat both forms of MS - relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) -which respond poorly to current therapies. ... In the Opera I and II clinical trials for RMS,

  • Sanofi Genzyme launches multiple sclerosis awareness campaign Sanofi Genzyme launches multiple sclerosis awareness campaign

    The vs.MS website also hosts videos, educational modules and the results of a global survey of people living with relapsing MS (RMS) in order to provide the MS community with ... The RMS survey questioned 1, 500 people and their care partners across

  • India's Supreme Court wants tighter clinical trial regulation India's Supreme Court wants tighter clinical trial regulation

    The Indian government needs to do more to stop illegal, unregulated clinical trials, according to Supreme Court judge Justice RM Lodha.

  • Oral agent meets MS trial primary endpoint

    Teriflunomide, a novel oral disease modifier under investigation by sanofi-aventis (S-A) for the treatment of relapsing multiple sclerosis (RMS), has been shown in the phase III TEMSO trial to ... TOWER and TENERE, two other phase III trials of

More from news
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...
Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...

Infographics